Baijin Life Science (HKG:1466) granted over 67.9 million share options to various directors and employees under a 2024 incentive scheme, according to a Friday Hong Kong bourse filing.
The options are exercisable into an equal number of ordinary shares in the firm's share capital for five years at HK$0.54 apiece.
The options are not subject to performance targets.
The jewelry maker now has no shares available for future grant under the scheme.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.